IDO inhibitors as monotherapy have generally shown limited efficacy in tumor treatment, and research has indicated a complex interplay between IDO1 expression, PD‐1 expression, and immune therapy resistance.267, 268, 269, 270. The gene discussed is IDO1; the disease is neoplasm.